StockNews.com Initiates Coverage on Oncternal Therapeutics (NASDAQ:ONCT)

Stock analysts at StockNews.com started coverage on shares of Oncternal Therapeutics (NASDAQ:ONCT) in a report issued on Sunday. The brokerage set a “hold” rating on the stock.

A number of other equities research analysts have also commented on the stock. Northland Capmk lowered shares of Oncternal Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Thursday, September 12th. HC Wainwright lowered their price objective on shares of Oncternal Therapeutics from $19.00 to $18.00 and set a “buy” rating for the company in a research note on Monday, August 12th. Brookline Capital Management reiterated a “hold” rating on shares of Oncternal Therapeutics in a report on Thursday, September 12th. Finally, Northland Securities restated a “market perform” rating and set a $2.00 price target on shares of Oncternal Therapeutics in a report on Thursday, September 12th. Four equities research analysts have rated the stock with a hold rating and one has issued a buy rating to the stock. According to data from MarketBeat.com, Oncternal Therapeutics has a consensus rating of “Hold” and a consensus price target of $20.00.

Oncternal Therapeutics Trading Up 2.7 %

Shares of NASDAQ:ONCT opened at $1.50 on Friday. The stock has a market capitalization of $4.44 million, a P/E ratio of -0.12 and a beta of 1.33. The stock’s 50-day moving average price is $2.14 and its 200-day moving average price is $5.64. Oncternal Therapeutics has a 12-month low of $1.05 and a 12-month high of $13.14.

Oncternal Therapeutics (NASDAQ:ONCT) last issued its earnings results on Thursday, August 8th. The company reported ($2.89) earnings per share for the quarter, beating the consensus estimate of ($3.03) by $0.14. The company had revenue of $0.80 million during the quarter, compared to analysts’ expectations of $0.24 million. Oncternal Therapeutics had a negative return on equity of 136.10% and a negative net margin of 1,948.70%. During the same period in the prior year, the business posted ($3.00) EPS. As a group, research analysts predict that Oncternal Therapeutics will post -12.43 EPS for the current year.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Oncternal Therapeutics stock. Quantum Private Wealth LLC purchased a new position in Oncternal Therapeutics, Inc. (NASDAQ:ONCT) in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 27,806 shares of the company’s stock, valued at approximately $250,000. Quantum Private Wealth LLC owned approximately 0.94% of Oncternal Therapeutics at the end of the most recent reporting period. Institutional investors and hedge funds own 16.05% of the company’s stock.

Oncternal Therapeutics Company Profile

Oncternal Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins, which is in Phase 1/2 clinical trial.